MUSE
20.10.2021 15:02:13 CEST | Business Wire | Press release
Interaxon Inc. (Muse® ), a leading consumer neurotechnology and meditation company, today announced the launch of the second generation of its popular EEG meditation & sleep headband, Muse S. This updated plush brain-sensing headband uses real-time biofeedback to help you learn the art of mediation as well as help you fall asleep, stay asleep and now go back to sleep if you awaken during the night.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005215/en/
Alongside the launch of the updated Muse S headband, Interaxon is launching an intelligent new kind of EEG-powered sleep experience that is designed to help put you to sleep and guide you back to sleep if you’ve woken during the night.
Interaxon has been excited to offer this never-before-seen sleep intervention after building on their successful release of sleep content & EEG sleep tracking insights to support healthy sleep habits. A recent 2021 study led by Western University, Cambridge Brain Science, Hatch, and Interaxon that used Muse S EEG-sleep support technology showed a 20% improvement in the Pittsburgh Sleep Quality Index, relative to controls wanting to improve their sleep.
“For many of us, increasingly busy days translate into busy minds at night and restless sleep. While sleep tracking can be helpful to gain insights on trends and changes in your sleep quality, tracking your sleep doesn’t provide immediate relief when you need it most,” said Walter Greenleaf, Chief Science Officer at Interaxon (Muse®). “According to the CDC, more than a third of American adults are not getting enough sleep on a regular basis with less than seven hours per day.1 This innovative new solution can help users get the rest they need to improve their overall wellness with a non-pharmaceutical sleep aid.”
Digital Sleeping Pills (DSPs)
Muse Digital Sleeping Pills or DSPs are designed to help you through the wind-down process by responding to your brain’s rhythms and helping you disengage from your busy mind. Muse S detects the natural changes in your brain activity as you fall asleep and uses those changes to gently fade out your audio to cue your brain that it’s time for sleep. If you wake in the night, Muse S uses the same Smart-Fade technology to automatically fade in the DSP content to guide you back to sleep again.
Sleep content preferences can vary widely from person to person. Some people are looking for a more engaging story to keep their mind from getting stuck in ruminating thoughts, while others may find a story too exciting to fall asleep to and prefer a softer, guided meditation or ambient soundscape. Depending on what type of content helps you fall asleep best, you can select a variety of different DSP’s to help you on your journey including all-new:
- Original, Classic, and Adventure Sleep Stories that have a voice narration of some of your favorite childhood stories & a variety of new original stories
- Ambient Sleep Soundscapes that offer soothing ambient music and harmonized sounds without a voice narrative
- Biofeedback Sleep Soundscapes that offer nature sounds and music that respond to biofeedback without a voice narrative
- Guided Sleep Meditations that have a meditation teacher guide you through a relaxing sleep meditation
In addition to the advanced EEG technology that Muse® is known for, the all-new second-generation Muse® S has improved signal quality for increased accuracy and enhanced battery performance with up to 50% reduction in charging time. Additionally, improved fit for a wider range of head sizes has been achieved with the same comfortable, adjustable, and washable fabric band.
Pricing and Availability
Muse® S (Gen 2) is now available for $399.99 USD at www.choosemuse.com and will be available on Amazon North America starting in 2022. Both first and second-generation Muse® S headbands will have access to the new Digital Sleep Pill (DSP) features free of charge with Gen 1 users gaining access in December of 2021.
To unlock Biofeedback+ and unlimited access to 500+ meditations with new content released monthly, you can subscribe to the Muse Premium Subscription for $12.99 USD per month or $94.99 USD per year.
In addition to a rich content library of more than 500 meditations from renowned meditation teachers, unlock access to a variety of relaxation techniques, Go-to-Sleep soundscapes, and in-depth courses with step-by-step instructions, such as The Sleep Basics course by Dr. Shelby Harris, an expert in behavioral sleep medicine. Additionally, you’ll have access to Biofeedback+ which is designed to allow you to see how your brain and body responds to external content whether it be music in Spotify, Audiobooks, or meditations in Headspace.
Now available at www.choosemuse.com .
About Muse ® by Interaxon Inc. :
At Muse®, our team of neuroscientists, meditation teachers, and engineers based out of Toronto who develop state-of-the-art experiences using research-grade EEG technology. Our goal is to help individuals build a rewarding meditation practice and live healthier, happier, more connected lives through human-centered technology. Our award-winning neurofeedback devices, and premium content offering of guided meditations with responsive learning functionality, is designed to help users meditate by providing real-time audio feedback on their meditative state through the Muse® companion app. We make the intangible, tangible. Muse is headquartered in Toronto, Canada, and has subsidiaries in the U.S. and Ireland.
More information about Muse® is available at www.choosemuse.com .
Milestones we’re excited about:
- More than 500,000 Musers globally
- Accessible: Muse is available in four languages, including English, Spanish, French and German
- Sessions of meditation with Muse ®: Over 100 million minutes to date and currently one of the largest brain data (EEG) collections in the world.
- Research institutions using Muse®: The Mayo Clinic, NASA, Harvard, MIT, U of T, UCL, UCSD, Inria, UVic, UBC, and many more.
- Meditating with Muse® works: Muse has been used in over 200 published studies, including Mayo Clinic who demonstrated meditating with Muse increases quality of life, and decreases stress and fatigue in cancer patients.
- Untangle Podcast : With more than 7 million plays, Untangle hosts Patricia Karpas and Ariel Garten interview thought-provoking authors, experts and leaders in areas related to mindfulness, sleep, neuroscience, brain health practices, and more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005215/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
